Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species

By Kalgutkar A. S.   Choo E.   Taylor T. J.   Marfat A.  

Xenobiotica, Vol. 34, Iss. 8, 2004-08 ,pp. : 755-770

Informa Healthcare

Access to resources Recommend Favorite

NMR Assignment of Rat Raf Kinase Inhibitor Protein

By Clark Matthew   McElheny Dan   Wojcik John   Kurutz Josh   Rosner Marsha   Koide Shohei  

Journal of Biomolecular NMR, Vol. 36, Iss. 5, 2006-12 ,pp. : 4-4

Springer Publishing Company

Access to resources Recommend Favorite

Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human

By Salphati Laurent   Pang Jodie   Plise Emile G.   Chou Bilin   Halladay Jason S.   Olivero Alan G.   Rudewicz Patrick J.   Tian Qingping   Wong Susan   Zhang Xiaolin  

Xenobiotica, Vol. 41, Iss. 12, 2011-12 ,pp. : 1088-1099

Informa Healthcare

Access to resources Recommend Favorite

Raf proteins and cancer: B-Raf is identified as a mutational target

By Mercer K.E.   Pritchard C.A.  

Biochimica et Biophysica Acta (BBA)/Reviews on Cancer, Vol. 1653, Iss. 1, 2003-06 ,pp. : 25-40

Elsevier

Access to resources Recommend Favorite

Difference in the Mechanism of Interaction of Raf-1 and B-Raf with H-Ras

By Shinkai M.   Masuda T.   Kariya K.I.   Tamada M.   Shirouzu M.   Yokoyama S.   Kataoka T.  

Biochemical and Biophysical Research Communications, Vol. 223, Iss. 3, 1996-06 ,pp. : 729-734

Elsevier

Access to resources Recommend Favorite